Evariste is an AI-driven Drug Discovery company
Patient-First Treatment
Evariste identifies and validates novel biomarkers to customize treatment to the patient
AI-Optimized Design
Evariste’s algorithmic modeling designs higher quality, differentiated molecules
Highly Automated R&D
Evariste has automated preclinical drug discovery enabling unprecedented scale and efficiency
Frobenius is Evariste's AI-enabled small molecule drug discovery platform
Using Frobenius, we are able to de-risk and progress projects with unrivaled efficiency
Each stage of our platform has been validated in challenging internal and collaborative projects
Frobenius Target
At Evariste we have developed the novel concept of synthetic lethal gene signatures, small panels of multi-omic biomarkers which reveal untargeted synthetic lethal interactions together with the patient population for which drugs targeting these genes will be most effective.
Our AI platform applies proprietary algorithms to large multi-omic biological and chemical datasets, including proprietary and public data. Targets are validated in disease-relevant models to ensure their clinical applicability. We identify specific predictive biomarkers or novel synthetic lethalities to ensure that the right patients will receive our treatments.
Frobenius Discovery
To translate the insights derived from Frobenius Target, Frobenius Discovery utilises information-rich hit finding tools to maximise the speed and success of ligand discovery.
We search ultra large libraries for hit-like chemical matter using statistically robust proprietary scoring functions. Probabilistic algorithms exploit the structure of combinatorial libraries, and facilitate virtual screening of libraries consisting of trillions of diverse compounds. The output of our screen is a diverse set of compounds in energetically favorable conformations hyper-enriched in key protein-ligand interactions.
We have successfully applied covalent fragment screens to find novel hit matter for previously undrugged protein families and target classes. The vast quantities of data generated by this technique maximises the speed of downstream development.
Frobenius Candidate
Frobenius Candidate designs and scores synthetically accessible molecules on a scale that would not be feasible for a team of chemists. Probabilistic modeling allows for principled combination of multiple endpoints, facilitating multi-parameter optimization. Our machine learning models are ideally suited to drug discovery as they are designed to work on small, noisy datasets.
The platform stands out not just for its ability to design synthetically accessible molecules, but also for its efficiency and efficacy. Through advanced statistical compound selection techniques, the platform consistently achieves a 10-fold increase in potency for every set of 30 compounds tested. Furthermore, in fewer than 50 compounds it has designed compounds with best-in-class selectivity against targets that are highly homologous. This level of precision and rapid optimization positions the Frobenius platform at the forefront of drug discovery, offering a transformative approach in an era where fast and efficient compound development is paramount.
Using Frobenius, we have developed a pipeline of precision oncology therapeutics
This includes best-in-class inhibitors of validated synthetic lethal targets expanded to new indications, and first-in-class inhibitors of novel targets
PKMYT1
Targeting PKMYT1 drives synthetic lethality in CCNE1 over-expressing cell lines, with clinical trials ongoing to explore this hypothesis. We have identified a novel biomarker for PKMYT1 synthetic lethality with potential for a significantly expanded patient population, and designed novel inhibitors with high potency and selectivity.
Undisclosed - Haematological Malignancies
Undisclosed target for heavily pretreated hematological malignancies. We have identified a new synthetic lethal target in a subset of acute myeloid leukemia and diffuse large B-cell lymphoma patients. This target is extremely novel and no enzymes of this class have been targeted with small molecule inhibitors or biologics.
Undisclosed - Synthetic Lethal
A well-validated target that is currently in clinical trials without a clear biomarker strategy. We have identified a novel synthetic lethal partner to allow rapid patient selection and have designed inhibitors with best-in-class potency and selectivity.
Discovery
Optimization
Enabling
Florencia has a MSc in Genomics Informatics where she worked on identifying and validating novel therapeutic targets for Oesophageal Adenocarcinoma. She has conducted studies in oncology, infectious diseases, & clinical genetics. Florencia aims to identify novel druggable targets in areas of unmet clinical need.
Florencia Skuras
BIOINFORMATICIAN
Noah is a graduate of the University of Oxford where he received a MSc in Biochemistry. His research focused on molecular dynamic simulations of mitochondrial supercomplexes and their interactions with lipid molecules. Since joining Evariste Noah has been developing the structure-based virtual screening pipeline, enriching the ability of Evariste's Hit Discovery platform.
Noah Harrison
CHEMOINFORMATICIAN
James graduated from his Mathematics doctorate from Magdalen College, University of Oxford, where he studied combinatorics, focusing on problems with an arithmetic flavor. James applies these techniques to solve combinatorial and statistical problems in drug discovery.
James Aaronson
QUANT ANALYST
Tracy has a PhD in Endocrinology from the University of Edinburgh and a MBA from Quantic School of Business and Technology. After the exciting field of AI enticed her from academia, Tracy worked at BenevolentAI in operations and programme management. She uses her scientific and business background to implement Evariste’s business goals.
Tracy Mak
OPERATIONS DIRECTOR
Partnerships
We work in collaboration with biotech companies to accelerate the development of small molecules for a range of target classes in diverse disease areas. Our AI platform is able to support and advance discovery at every stage of preclinical development.
For any collaboration or business development inquiries:
Our Partners
Contact us
News & updates
Stay updated with Evariste's blogposts
Latest News
